Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guiling Zhao

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Bioorganic & Medicinal Chemistry Letters|January 18, 2014
Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Guiling Zhao, Timm Baumeister, et al.
Journal of Medicinal Chemistry|April 27, 2013
Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Journal of Medicinal Chemistry|February 17, 2012
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic propertiesSimon Mathieu, Stefan N Gradl, Li Ren, et al.
Journal of Medicinal Chemistry|January 11, 2014
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Anthony M Giannetti, Xiaozhang Zheng, Nicholas J Skelton, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2015
Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubilityMark Zak, Bianca M Liederer, Deepak Sampath, et al.
Journal of Medicinal Chemistry|July 18, 2013
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Journal of Medicinal Chemistry|May 23, 2025
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer TherapyDillon H Miles, Manjunath Lamani, Srinivas Reddy Paladugu, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2019
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signalingMark Zak, Emily J Hanan, Patrick Lupardus, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2013
Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition propertiesJanet Gunzner-Toste, Guiling Zhao, Paul Bauer, et al.
Journal of Medicinal Chemistry|December 12, 2017
Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease SpecificityBinQing Wei, Janet Gunzner-Toste, Hui Yao, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Bioorganic & Medicinal Chemistry Letters|January 18, 2014
Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Peter S Dragovich, Guiling Zhao, Timm Baumeister, et al.
Journal of Medicinal Chemistry|April 27, 2013
Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Journal of Medicinal Chemistry|February 17, 2012
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic propertiesSimon Mathieu, Stefan N Gradl, Li Ren, et al.
Journal of Medicinal Chemistry|January 11, 2014
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Anthony M Giannetti, Xiaozhang Zheng, Nicholas J Skelton, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2015
Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubilityMark Zak, Bianca M Liederer, Deepak Sampath, et al.
Journal of Medicinal Chemistry|July 18, 2013
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Journal of Medicinal Chemistry|May 23, 2025
Discovery of AB801, a Potent and Selective Inhibitor of AXL Receptor Tyrosine Kinase for Use in Cancer TherapyDillon H Miles, Manjunath Lamani, Srinivas Reddy Paladugu, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2019
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signalingMark Zak, Emily J Hanan, Patrick Lupardus, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2013
Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition propertiesJanet Gunzner-Toste, Guiling Zhao, Paul Bauer, et al.
Journal of Medicinal Chemistry|December 12, 2017
Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease SpecificityBinQing Wei, Janet Gunzner-Toste, Hui Yao, et al.
Pageof 10